In the comparison of patients with post-Tx LOXL2 levels < 2.08 versus  ≥ 2.08 ng/mL, the cumulative incidence rates of HCC were 1.9% versus 7.1% at 1 year, 9.1% versus 18.2% at 3 years, and 11.9% versus 30.5% at 5 years. This evidence concerns the gene LOXL2 and hepatocellular carcinoma.